Interní Med. 2017; 19(1): 20-22 | DOI: 10.36290/int.2017.003
The news in multiple myeloma treatment
- Interní hematologická a onkologická klinika, FN Brno
Nowadays, the treatment of multiple myeloma is undergoing dynamic development. New antimyeloma drugs – carfilzomib,
ixazomib, pomalidomid, daratumumab, elotuzumab and panobinostat – have been tested in cilnical trials. The use of these new
drugs is beneficial for patients with relapsed multiple myeloma and primarily can improve prognosis of refractory disease. We
expect that many of these drugs will become regular parts of standard medical protocols for relapse and most probably also for
the initial treatment. Carfilzomib and pomalidomid have extended the progression free survival almost twice when compared to
standard treatment. Also, monoclonal antibodies are a hopeful group of drugs, which show a high efficiency based on a different
mechanism of effect than current treatment. The aim of this review is to present results of clinical trials describing use of these
new drugs in treatment of multiple myeloma.
Keywords: multiple myeloma, immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies
Published: February 1, 2017 Show citation
References
- Hájek R, Krejčí M, Pour, et al. Multiple myeloma, Klin Onkol 2011; 24: 10-13.
- Kumar S, Rajkumar S, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies, Blood 2008; 111: 2516-2520.
Go to original source... 
Go to PubMed... - San-Miguel JF, Mateos MV. Can multiple myeloma become a curable disease? Haematologica, 2011; 96: 1246-1248. Go to original source... Go to PubMed...
- Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood. 2015; 126(3): 300-310. Go to original source... Go to PubMed...
- Muchtar E, Gertz MA, Magen H. A practical review on carfilzomib in multiple myeloma. Eur J Haematol. 2016; 96: 564-577. Go to original source... Go to PubMed...
- Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016; 17: 27-38. Go to original source... Go to PubMed...
- Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372(2): 142-152. Go to original source... Go to PubMed...
- Moreau P, Masszi T, Grzasko N, Bahlis NJ, et.at. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma; N Engl J Med 2016; 374: 1621-1634. Go to original source... Go to PubMed...
- Millennium Pharmaceuticals, Inc, IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma, (September 2016) Avaliable in https://www.clinicaltrials.gov/ct2/show/NCT01850524 NLM indentifier NCT01850524.
- Kotla V, Goel S, Nischal S et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009; 2: 36. Go to original source... Go to PubMed...
- Mark TM, Coleman M, Niesvizky R. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. Leuk Res. 2014; 38(5): 517-524. Go to original source... Go to PubMed...
- San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14(11): 1055-1066. Go to original source... Go to PubMed...